Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate

Review

(4514) Views  (1539) Full article downloads

Authors: Veerle P Persy, Geert J Behets, Marc E De Broe, Patrick C D’Haese

Published Date April 2009 Volume 2009:2(Default) Pages 1 - 8

DOI: http://dx.doi.org/10.2147/IJNRD.S5007

Veerle P Persy, Geert J Behets, Marc E De Broe, Patrick C D’Haese

Laboratory of Pathophysiology, University of Antwerp, Belgium

Abstract: Elevated serum phosphate levels as a consequence of chronic kidney disease (CKD) contribute to the increased cardiovascular risk observed in dialysis patients. Protein restriction and dialysis fail to adequately prevent hyperphosphatemia, and in general treatment with oral phosphate binding agents is necessary in patients with advanced CKD. Phosphate plays a pivotal role in the development of vascular calcification, one of the factors contributing to increased cardiovascular risk in CKD patients. Treatment of hyperphosphatemia with standard calcium-based phosphate binders and vitamin D compounds can induce hypercalcemic episodes, increase the Ca × PO₄ product and thus add to the risk of ectopic mineralization. In this review, recent clinical as well as experimental data on lanthanum carbonate, a novel, non-calcium, non-resin phosphate binding agent are summarized. Although lanthanum is a metal cation no aluminium-like toxicity is observed since the bioavailability of lanthanum is extremely low and its metabolism differs from that of aluminium. Clinical studies now document the absence of toxic effects of lanthanum for up to 6 years of follow-up. The effects of lanthanum on bone, vasculature and brain are discussed and put in perspective with lanthanum pharmacokinetics.

Keywords: lanthanum carbonate, phosphate binding, chronic kidney disease